Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Sleep apnoea is a term which refers to frequent breathing pauses during sleep. Breathing can stop at night due to the upper airway collapsing (Obstructive sleep apnoea)or reduced signals from the brain driving breathing (central sleep apnoea). Clinical observation has noticed that patients on opiates have an increase in sleep apnoea.
Hypothesis: This study looks at the relationship of opiates (when used for patients chronic pain) and the occurrence of sleep apnoea. It is expected that there will be an increase in sleep apnoea (particularly of the central variant) particularly in patients on long term opiates.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aims
1. To define the prevalence of sleep disordered breathing in a group of patients on oral morphine for chronic pain.
2. To determine the prevalence of respiratory failure in this cohort of patients. Patients on long term opiates (\>6 months) from an outpatient pain clinic population on long acting morphine formulations \> 40 mg/day, Oxycontin 30 mg/day, and Methadone \> 20 mg/day were prospectively recruited. Home polysomnograms were done on them. During their clinical review they have spirometry, arterial blood gases, psychomotor vigilance tests done on them.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable opiate dose for 2 weeks
* Lives within 80KM of FMC
Exclusion Criteria
* Severe COPD
* Major Psychiatric illness
* History of substance abuse in the last 3 months
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Flinders Medical Centre
OTHER_GOV
Adelaide Institute for Sleep Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adelaide Institute of Sleep Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anand R Rose, MD,FRACP
Role: PRINCIPAL_INVESTIGATOR
Adelaide Institute of Sleep Health
Doug McEvoy, MD, FRACP
Role: STUDY_DIRECTOR
Adelaide Institute of Sleep Health, Repatriation General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pain Management Unit, Flinders Medical Centre
Bedford Park, South Australia, Australia
Adelaide Institute of Sleep Health, Repatriation General Hospital,
Daw Park, South Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dilip Kapur, FRCA, FANZCA
Role: primary
Anand R Rose, MD,FRACP
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
50/07
Identifier Type: -
Identifier Source: org_study_id